FundedIQ
Biotechnology

Talaris Therapeutics: Funding, Investors & Team (Nov 2026)

Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

talaristx.com LinkedIn Wellesley, United States 51-100 employees
Total raised
$115M
Rounds
1
Latest
Undisclosed round
Oct 2020

Talaris Therapeutics has raised $115M across 1 funding round on record, the most recent an undisclosed round of $115M announced in Oct 2020.

That round is above the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Talaris Therapeutics Company Profile and Key Stats

Total funding raised
$115M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$115M in Oct 2020
Employees
51-100
reported band
Headquarters
Wellesley, United States

Latest funding round on record: Oct 2020.

Talaris Therapeutics Funding Rounds

Date
Round
Amount
Undisclosed round
$115M

Talaris Therapeutics Founders and Leadership Team

Name
Role
Contact
Scott Requadt
CEO
Locked

Contact details for the Talaris Therapeutics team: 1 of 1 has an email address on file.

Start 14-day free trial →

Talaris Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,188
$8.9M
30,615
$7.8M

Talaris Therapeutics' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Talaris Therapeutics in Biotechnology and Wellesley

Companies Similar to Talaris Therapeutics

Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…

Seed $4.5M

Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.

Pre-Seed $5.3M

Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…

Series B $25.0M

Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…

Undisclosed round $380k

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…

Series C $100M

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…

Series B $41.9M

Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…

Series A $6.0M

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…

Series D —

Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…

Undisclosed round $21.5M

100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…

Pre-Seed $110k

MEND is a company focused on life sciences, determined to assist individuals in achieving better health…

Undisclosed round $1.5M

Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…

Series B $50.0M

Talaris Therapeutics Funding FAQs

What does Talaris Therapeutics do?

Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

How much funding has Talaris Therapeutics raised?

Talaris Therapeutics has raised $115M across 1 round on record. The most recent is an undisclosed round of $115M announced in Oct 2020.

When did Talaris Therapeutics last raise funding?

Talaris Therapeutics' most recent funding round on record is an undisclosed round of $115M, announced in Oct 2020.

Who is the CEO of Talaris Therapeutics?

Scott Requadt is listed as CEO at Talaris Therapeutics.

Where is Talaris Therapeutics headquartered?

Talaris Therapeutics is based in Wellesley, Massachusetts, United States.

How many employees does Talaris Therapeutics have?

Talaris Therapeutics is in the 51-100 employee band.

How does Talaris Therapeutics' funding compare to other Biotechnology startups?

Talaris Therapeutics' latest round of $115M is above the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.

About FundedIQ's Talaris Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Talaris Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.